Prognostic Value of Biomarkers in RCC


Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content